Evidence map›Paper›PMID 38657156›Full record

ReviewJournal of computer assisted tomography

Diagnostic Anatomic Imaging for Neuroendocrine Neoplasms: Maximizing Strengths and Mitigating Weaknesses.

Mina Hesami, Michael Blake, Mark A Anderson, Luigi Asmundo, Aoife Kilcoyne, Zahra Najmi, Peter D Caravan, Ciprian Catana, Cynthia Czawlytko, Shadi Abdar Esfahani and 6 more

Open access · greenAbstract readReview
In one paragraph

Review in Journal of computer assisted tomography. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 4 countries.

Mina HesamiFrom the Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Michael BlakeFrom the Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Mark A AndersonFrom the Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Luigi Asmundo
Aoife KilcoyneFrom the Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Zahra NajmiFrom the Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Peter D CaravanFrom the Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Ciprian CatanaFrom the Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Cynthia CzawlytkoFrom the Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Shadi Abdar EsfahaniFrom the Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Avinash R KambadakoneFrom the Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Anthony SamirFrom the Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Shaunagh McDermottFrom the Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Liran DomachevskyDepartment of Nuclear Medicine, The Chaim Sheba Medical Center, Tel Hashomer, Israel.
Stephan UrsprungDepartment of Radiology, University Hospital Tuebingen, Tuebingen, Germany.
Onofrio A CatalanoFrom the Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Massachusetts General Hospital · USHarvard University · USSheba Medical Center · ILUniversity of Milan · ITUniversity of Tübingen · DE

Funding

Molecular Imaging of Fibrosis for Improved Treatment Planning of Pancreatic Ductal AdenocarcinomaK08CA259626 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Shadi Abdar Esfahani · 2022 to 2026
$1.3M
NCI NIH HHS K08 CA259626
6 · The paper itself

Abstract

abstractNeuroendocrine neoplasms are a heterogeneous group of gastrointestinal and lung tumors. Their diverse clinical manifestations, variable locations, and heterogeneity present notable diagnostic challenges. This article delves into the imaging modalities vital for their detection and characterization. Computed tomography is essential for initial assessment and staging. At the same time, magnetic resonance imaging (MRI) is particularly adept for liver, pancreatic, osseous, and rectal imaging, offering superior soft tissue contrast. The article also highlights the limitations of these imaging techniques, such as MRI's inability to effectively evaluate the cortical bone and the questioned cost-effectiveness of computed tomography and MRI for detecting specific gastric lesions. By emphasizing the strengths and weaknesses of these imaging techniques, the review offers insights into optimizing their utilization for improved diagnosis, staging, and therapeutic management of neuroendocrine neoplasms.

Indexed as

Magnetic Resonance ImagingNeuroendocrine TumorsTomography, X-Ray ComputedHumans

Identifiers

PMID38657156
PMCPMC11245376
OpenAlexW4395111029

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.